Harnessing the power of artificial intelligence to combat infectious diseases: Progress, challenges, and future outlook
-
GRAPHICAL ABSTRACT
DownLoad:
Full size image
-
PUBLIC SUMMARY
-
Artificial intelligence technologies show significant promise in preventing and controlling infectious diseases.
Advances made across all outbreak stages: pre-pandemic, early pandemic, pandemic, and periodic epidemics.
Deep learning facilitates early detection, risk assessment, policy formulation, and vaccine development.
Challenges arise from data quantity/quality, model complexity/interpretability, and individual privacy concerns.
Promising directions lie in the deep integration of deep learning models with specific biological knowledge.
-
-
ABSTRACT
The rapid emergence and global spread of infectious diseases pose significant challenges to public health. In recent years, artificial intelligence (AI) technologies have shown great potential in enhancing our ability to prevent, detect, and control infectious disease outbreaks. However, as a growing interdisciplinarity field, a gap exists between AI scientists and infectious disease biologists, limiting the full potential of AI in this field. This review provides a comprehensive overview of the applications of AI in infectious diseases, focusing on the progress along the four stages of outbreaks: pre-pandemic, early pandemic, pandemic, and periodic epidemic stages. We discuss AI methods in early detection and risk assessment, outbreak surveillance, diagnosis and control, and understanding pathogenic mechanisms. We also propose the primary limitations, challenges, and potential solutions associated with AI tools in public health contexts while examining crucial considerations for future enhanced implementation. By harnessing the power of AI, we can develop more precise and targeted strategies to mitigate the burden of infectious diseases and improve global health. -
-
REFERENCES
[1] Msemburi, W., Karlinsky, A., Knutson, V., et al. (2023). The WHO estimates of excess mortality associated with the COVID-19 pandemic. Nature 613: 130−137. DOI: 10.1038/s41586-022-05522-2. [2] WHO. (2024). Prioritizing diseases for research and development in emergency contexts. https://www.who.int/activities/prioritizing-diseases-for-research-and-development-in-emergency-contexts. [3] Brownstein, J.S., Rader, B., Astley, C.M., et al. (2023). Advances in artificial intelligence for infectious-disease surveillance. N. Engl. J. Med. 388: 1597−1607. DOI: 10.1056/NEJMra2119215. [4] Wong, F., de la Fuente-Nunez, C., and Collins, J.J. (2023). Leveraging artificial intelligence in the fight against infectious diseases. Science 381: 164−170. DOI: 10.1126/science.adh1114. [5] Topol, E.J. (2019). High-performance medicine: The convergence of human and artificial intelligence. Nat. Med. 25: 44−56. DOI: 10.1038/s41591-018-0300-7. [6] Aiello, A.E., Renson, A., and Zivich, P.N. (2020). Social media- and internet-based disease surveillance for public health. Annu. Rev. Public Health 41: 101−118. DOI: 10.1146/annurev-publhealth-040119-094402. [7] Ginsberg, J., Mohebbi, M.H., Patel, R.S., et al. (2009). Detecting influenza epidemics using search engine query data. Nature 457: 1012−1014. DOI: 10.1038/nature07634. [8] Lazer, D., Kennedy, R., King, G., et al. (2014). The parable of Google Flu: Traps in big data analysis. Science 343: 1203−1205. DOI: 10.1126/science.1248506. [9] Kogan, N.E., Clemente, L., Liautaud, P., et al. (2021). An early warning approach to monitor COVID-19 activity with multiple digital traces in near real time. Sci. Adv. 7: eabd6989. DOI: 10.1126/sciadv.abd6989. [10] Stolerman, L.M., Clemente, L., Poirier, C., et al. (2023). Using digital traces to build prospective and real-time county-level early warning systems to anticipate COVID-19 outbreaks in the United States. Sci. Adv. 9: eabq0199. DOI: 10.1126/sciadv.abq0199. [11] Jahn, K., Dreifuss, D., Topolsky, I., et al. (2022). Early detection and surveillance of SARS-CoV-2 genomic variants in wastewater using COJAC. Nat. Microbiol. 7: 1151−1160. DOI: 10.1038/s41564-022-01185-x. [12] Chia, P.Y., Coleman, K.K., Tan, Y.K., et al. (2020). Detection of air and surface contamination by SARS-CoV-2 in hospital rooms of infected patients. Nat. Commun. 11: 2800. DOI: 10.1038/s41467-020-16670-2. [13] Doremalen, N.V., Bushmaker, T., Morris, D.H., et al. (2020). Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N. Engl. J. Med. 382: 1564−1567. DOI: 10.1056/NEJMc2004973. [14] Karthikeyan, S., Levy, J.I., De Hoff, P., et al. (2022). Wastewater sequencing reveals early cryptic SARS-CoV-2 variant transmission. Nature 609: 101−108. DOI: 10.1038/s41586-022-05049-6. [15] Jones, K.E., Patel, N.G., Levy, M.A., et al. (2008). Global trends in emerging infectious diseases. Nature 451: 990−993. DOI: 10.1038/nature06536. [16] Carroll, D., Daszak, P., Wolfe, N.D., et al. (2018). The global virome project. Science 359: 872−874. DOI: 10.1126/science.aap7463. [17] Grange, Z.L., Goldstein, T., Johnson, C.K., et al. (2021). Ranking the risk of animal-to-human spillover for newly discovered viruses. Proc. Natl. Acad. Sci. U. S. A. 118: e2002324118. DOI: 10.1073/pnas.2002324118. [18] Wardeh, M., Blagrove, M.S.C., Sharkey, K.J., et al. (2021). Divide-and-conquer: Machine-learning integrates mammalian and viral traits with network features to predict virus-mammal associations. Nat. Commun. 12: 3954. DOI: 10.1038/s41467-021-24085-w. [19] Levy, J.I., Andersen, K.G., Knight, R., et al. (2023). Wastewater surveillance for public health. Science 379: 26−27. DOI: 10.1126/science.ade2503. [20] Luksza, M. and Lassig, M. (2014). A predictive fitness model for influenza. Nature 507: 57−61. DOI: 10.1038/nature13087. [21] Shu, Y. and McCauley, J. (2017). GISAID: Global initiative on sharing all influenza data–from vision to reality. Eurosurveillance 22: 30494. DOI: 10.2807/1560-7917.ES.2017.22.13.30494. [22] Obermeyer, F., Jankowiak, M., Barkas, N., et al. (2022). Analysis of 6.4 million SARS-CoV-2 genomes identifies mutations associated with fitness. Science 376 : 1327-1332. DOI: 10.1126/science.abm1208. [23] Maher, M.C., Bartha, I., Weaver, S., et al. (2022). Predicting the mutational drivers of future SARS-CoV-2 variants of concern. Sci. Transl. Med. 14: eabk3445. DOI: 10.1126/scitranslmed.abk3445. [24] Hie, B., Zhong, E.D., Berger, B., et al. (2021). Learning the language of viral evolution and escape. Science 371: 284−288. DOI: 10.1126/science.abd7331. [25] Thadani, N.N., Gurev, S., Notin, P., et al. (2023). Learning from prepandemic data to forecast viral escape. Nature 622: 818−825. DOI: 10.1038/s41586-023-06617-0. [26] Brauner, J.M., Mindermann, S., Sharma, M., et al. (2021). Inferring the effectiveness of government interventions against COVID-19. Science 371: eabd9338. DOI: 10.1126/science.abd9338. [27] Chang, S., Pierson, E., Koh, P.W., et al. (2021). Mobility network models of COVID-19 explain inequities and inform reopening. Nature 589: 82−87. DOI: 10.1038/s41586-020-2923-3. [28] Leung, K., Wu, J.T., and Leung, G.M. (2021). Real-time tracking and prediction of COVID-19 infection using digital proxies of population mobility and mixing. Nat. Commun. 12: 1501. DOI: 10.1038/s41467-021-21776-2. [29] Stockdale, J.E., Susvitasari, K., Tupper, P., et al. (2023). Genomic epidemiology offers high resolution estimates of serial intervals for COVID-19. Nat. Commun. 14: 4830. DOI: 10.1038/s41467-023-40544-y. [30] Valdano, E., Colombi, D., Poletto, C., et al. (2023). Epidemic graph diagrams as analytics for epidemic control in the data-rich era. Nat. Commun. 14: 8472. DOI: 10.1038/s41467-023-43856-1. [31] Cooper, B.S., Evans, S., Jafari, Y., et al. (2023). The burden and dynamics of hospital-acquired SARS-CoV-2 in England. Nature 623: 132−138. DOI: 10.1038/s41586-023-06634-z. [32] Ward, T., Johnsen, A., Ng, S., et al. (2022). Forecasting SARS-CoV-2 transmission and clinical risk at small spatial scales by the application of machine learning architectures to syndromic surveillance data. Nat. Mach. Intell. 4: 814−827. DOI: 10.1038/s42256-022-00538-9. [33] Nicholson, G., Lehmann, B., Padellini, T., et al. (2022). Improving local prevalence estimates of SARS-CoV-2 infections using a causal debiasing framework. Nat. Microbiol. 7: 97−107. DOI: 10.1038/s41564-021-01029-0. [34] Yang, W. and Shaman, J. (2021). Development of a model-inference system for estimating epidemiological characteristics of SARS-CoV-2 variants of concern. Nat. Commun. 12: 5573. DOI: 10.1038/s41467-021-25913-9. [35] Lloyd-Smith, J.O., Schreiber, S.J., Kopp, P.E., et al. (2005). Superspreading and the effect of individual variation on disease emergence. Nature 438: 355−359. DOI: 10.1038/nature04153. [36] Lemieux, J.E., Siddle, K.J., Shaw, B.M., et al. (2021). Phylogenetic analysis of SARS-CoV-2 in Boston highlights the impact of superspreading events. Science 371: eabe3261. DOI: 10.1126/science.abe3261. [37] Lau, M.S.Y., Grenfell, B., Thomas, M., et al. (2020). Characterizing superspreading events and age-specific infectiousness of SARS-CoV-2 transmission in Georgia, USA. Proc. Natl. Acad. Sci. U. S. A. 117: 22430−22435. DOI: 10.1073/pnas.2011802117. [38] Gomes, B. and Ashley, E.A. (2023). Artificial intelligence in molecular medicine. N. Engl. J. Med. 388: 2456−2465. DOI: 10.1056/NEJMra2204787. [39] Sadybekov, A.V. and Katritch, V. (2023). Computational approaches streamlining drug discovery. Nature 616: 673−685. DOI: 10.1038/s41586-023-05905-z. [40] Mullowney, M.W., Duncan, K.R., Elsayed, S.S., et al. (2023). Artificial intelligence for natural product drug discovery. Nat. Rev. Drug Discov. 22: 895−916. DOI: 10.1038/s41573-023-00774-7. [41] Pandey, M., Fernandez, M., Gentile, F., et al. (2022). The transformational role of GPU computing and deep learning in drug discovery. Nat. Mach. Intell. 4: 211−221. DOI: 10.1038/s42256-022-00463-x. [42] Turbe, V., Herbst, C., Mngomezulu, T., et al. (2021). Deep learning of HIV field-based rapid tests. Nat. Med. 27: 1165−1170. DOI: 10.1038/s41591-021-01384-9. [43] Huang, S.C., Chaudhari, A.S., Langlotz, C.P., et al. (2022). Developing medical imaging AI for emerging infectious diseases. Nat. Commun. 13: 7060. DOI: 10.1038/s41467-022-34234-4. [44] Rajpurkar, P. and Lungren, M.P. (2023). The current and future state of AI interpretation of medical images. N. Engl. J. Med. 388: 1981−1990. DOI: 10.1056/NEJMra2301725. [45] Jin, C., Chen, W., Cao, Y., et al. (2020). Development and evaluation of an artificial intelligence system for COVID-19 diagnosis. Nat. Commun. 11: 5088. DOI: 10.1038/s41467-020-18685-1. [46] Mei, X., Lee, H.-C., Diao, K.-y., et al. (2020). Artificial intelligence–enabled rapid diagnosis of patients with COVID-19. Nat. Med. 26: 1224−1228. DOI: 10.1038/s41591-020-0931-3. [47] Dvijotham, K.D., Winkens, J., Barsbey, M., et al. (2023). Enhancing the reliability and accuracy of AI-enabled diagnosis via complementarity-driven deferral to clinicians. Nat. Med. 29: 1814−1820. DOI: 10.1038/s41591-023-02437-x. [48] Roberts, M., Driggs, D., Thorpe, M., et al. (2021). Common pitfalls and recommendations for using machine learning to detect and prognosticate for COVID-19 using chest radiographs and CT scans. Nat. Mach. Intell. 3: 199−217. DOI: 10.1038/s42256-021-00307-0. [49] Bai, X., Wang, H., Ma, L., et al. (2021). Advancing COVID-19 diagnosis with privacy-preserving collaboration in artificial intelligence. Nat. Mach. Intell. 3: 1081−1089. DOI: 10.1038/s42256-021-00421-z. [50] Ktena, I., Wiles, O., Albuquerque, I., et al. (2024). Generative models improve fairness of medical classifiers under distribution shifts. Nat. Med. 30: 1166−1173. DOI: 10.1038/s41591-024-02838-6. [51] Liang, W., Yao, J., Chen, A., et al. (2020). Early triage of critically ill COVID-19 patients using deep learning. Nat. Commun. 11: 3543. DOI: 10.1038/s41467-020-17280-8. [52] Hoertel, N., Blachier, M., Blanco, C., et al. (2020). A stochastic agent-based model of the SARS-CoV-2 epidemic in France. Nat. Med. 26: 1417−1421. DOI: 10.1038/s41591-020-1001-6. [53] Schwab, P., Mehrjou, A., Parbhoo, S., et al. (2021). Real-time prediction of COVID-19 related mortality using electronic health records. Nat. Commun. 12: 1058. DOI: 10.1038/s41467-020-20816-7. [54] Gao, J., Heintz, J., Mack, C., et al. (2023). Evidence-driven spatiotemporal COVID-19 hospitalization prediction with Ising dynamics. Nat. Commun. 14: 3093. DOI: 10.1038/s41467-023-38756-3. [55] Tomasev, N., Harris, N., Baur, S., et al. (2021). Use of deep learning to develop continuous-risk models for adverse event prediction from electronic health records. Nat. Protoc. 16: 2765−2787. DOI: 10.1038/s41596-021-00513-5. [56] Gao, Y., Cai, G.Y., Fang, W., et al. (2020). Machine learning based early warning system enables accurate mortality risk prediction for COVID-19. Nat. Commun. 11: 5033. DOI: 10.1038/s41467-020-18684-2. [57] Dayan, I., Roth, H.R., Zhong, A., et al. (2021). Federated learning for predicting clinical outcomes in patients with COVID-19. Nat. Med. 27: 1735−1743. DOI: 10.1038/s41591-021-01506-3. [58] Lassau, N., Ammari, S., Chouzenoux, E., et al. (2021). Integrating deep learning CT-scan model, biological and clinical variables to predict severity of COVID-19 patients. Nat. Commun. 12: 634. DOI: 10.1038/s41467-020-20657-4. [59] Yan, L., Zhang, H.-T., Goncalves, J., et al. (2020). An interpretable mortality prediction model for COVID-19 patients. Nat. Mach. Intell. 2: 283−288. DOI: 10.1038/s42256-020-0180-7. [60] Devaux, Y., Zhang, L., Lumley, A.I., et al. (2024). Development of a long noncoding RNA-based machine learning model to predict COVID-19 in-hospital mortality. Nat. Commun. 15: 4259. DOI: 10.1038/s41467-024-47557-1. [61] Lauritsen, S.M., Kristensen, M., Olsen, M.V., et al. (2020). Explainable artificial intelligence model to predict acute critical illness from electronic health records. Nat. Commun. 11: 3852. DOI: 10.1038/s41467-020-17431-x. [62] Thompson, E.J., Williams, D.M., Walker, A.J., et al. (2022). Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nat. Commun. 13: 3528. DOI: 10.1038/s41467-022-30836-0. [63] Zang, C., Zhang, Y., Xu, J., et al. (2023). Data-driven analysis to understand long COVID using electronic health records from the RECOVER initiative. Nat. Commun. 14: 1948. DOI: 10.1038/s41467-023-37653-z. [64] Zhang, H., Zang, C., Xu, Z., et al. (2023). Data-driven identification of post-acute SARS-CoV-2 infection subphenotypes. Nat. Med. 29: 226−235. DOI: 10.1038/s41591-022-02116-3. [65] Ferretti, L., Wymant, C., Kendall, M., et al. (2020). Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing. Science 368: eabb6936. DOI: 10.1126/science.abb6936. [66] Kucharski, A.J., Klepac, P., Conlan, A.J.K., et al. (2020). Effectiveness of isolation, testing, contact tracing, and physical distancing on reducing transmission of SARS-CoV-2 in different settings: A mathematical modelling study. Lancet Infect. Dis. 20: 1151−1160. DOI: 10.1016/S1473-3099(20)30457-6. [67] Kendall, M., Tsallis, D., Wymant, C., et al. (2023). Epidemiological impacts of the NHS COVID-19 app in England and Wales throughout its first year. Nat. Commun. 14: 858. DOI: 10.1038/s41467-023-36495-z. [68] Wymant, C., Ferretti, L., Tsallis, D., et al. (2021). The epidemiological impact of the NHS COVID-19 app. Nature 594: 408−412. DOI: 10.1038/s41586-021-03606-z. [69] Ferretti, L., Wymant, C., Petrie, J., et al. (2024). Digital measurement of SARS-CoV-2 transmission risk from 7 million contacts. Nature 626: 145−150. DOI: 10.1038/s41586-023-06952-2. [70] Kretzschmar, M.E., Rozhnova, G., Bootsma, M.C.J., et al. (2020). Impact of delays on effectiveness of contact tracing strategies for COVID-19: A modelling study. Lancet Public Health 5: e452−e459. DOI: 10.1016/S2468-2667(20)30157-2. [71] Colizza, V., Grill, E., Mikolajczyk, R., et al. (2021). Time to evaluate COVID-19 contact-tracing apps. Nat. Med. 27: 361−362. DOI: 10.1038/s41591-021-01236-6. [72] Pandit, J.A., Radin, J.M., Quer, G., et al. (2022). Smartphone apps in the COVID-19 pandemic. Nat. Biotechnol. 40: 1013−1022. DOI: 10.1038/s41587-022-01350-x. [73] Flaxman, S., Mishra, S., Gandy, A., et al. (2020). Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature 584: 257−261. DOI: 10.1038/s41586-020-2405-7. [74] Kraemer, M.U.G., Yang, C.-H., Gutierrez, B., et al. (2020). The effect of human mobility and control measures on the COVID-19 epidemic in China. Science 368: 493−497. DOI: 10.1126/science.abb4218. [75] Candido, D.S., Claro, I.M., de Jesus, J.G., et al. (2020). Evolution and epidemic spread of SARS-CoV-2 in Brazil. Science 369: 1255−1260. DOI: 10.1126/science.abd2161. [76] Haug, N., Geyrhofer, L., Londei, A., et al. (2020). Ranking the effectiveness of worldwide COVID-19 government interventions. Nat. Hum. Behav. 4: 1303−1312. DOI: 10.1038/s41562-020-01009-0. [77] Ge, Y., Wu, X., Zhang, W., et al. (2023). Effects of public-health measures for zeroing out different SARS-CoV-2 variants. Nat. Commun. 14: 5270. DOI: 10.1038/s41467-023-40940-4. [78] Li, Y., Campbell, H., Kulkarni, D., et al. (2021). The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-CoV-2: A modelling study across 131 countries. Lancet Infect. Dis. 21: 193−202. DOI: 10.1016/S1473-3099(20)30785-4. [79] Zhang, H., Zhang, L., Lin, A., et al. (2023). Algorithm for optimized mRNA design improves stability and immunogenicity. Nature 621: 396−403. DOI: 10.1038/s41586-023-06127-z. [80] Abramson, J., Adler, J., Dunger, J., et al. (2024). Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 630: 493−500. DOI: 10.1038/s41586-024-07487-w. [81] Lutz, I.D., Wang, S., Norn, C., et al. (2023). Top-down design of protein architectures with reinforcement learning. Science 380: 266−273. DOI: 10.1126/science.adf6591. [82] Loomba, S., de Figueiredo, A., Piatek, S.J., et al. (2021). Measuring the impact of COVID-19 vaccine misinformation on vaccination intent in the UK and USA. Nat. Hum. Behav. 5: 337−348. DOI: 10.1038/s41562-021-01056-1. [83] Band, G., Le, Q.S., Clarke, G.M., et al. (2019). Insights into malaria susceptibility using genome-wide data on 17,000 individuals from Africa, Asia and Oceania. Nat. Commun. 10: 5732. DOI: 10.1038/s41467-019-13480-z. [84] Sveinbjornsson, G., Gudbjartsson, D.F., Halldorsson, B.V., et al. (2016). HLA class II sequence variants influence tuberculosis risk in populations of European ancestry. Nat. Genet. 48: 318−322. DOI: 10.1038/ng.3498. [85] Zheng, R., Li, Z., He, F., et al. (2018). Genome-wide association study identifies two risk loci for tuberculosis in Han Chinese. Nat. Commun. 9: 4072. DOI: 10.1038/s41467-018-06539-w. [86] The International HIV Controllers Study. (2010). The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 330: 1551−1557. DOI: 10.1126/science.1195271. [87] Niemi, M.E.K., Karjalainen, J., Liao, R.G., et al. (2021). Mapping the human genetic architecture of COVID-19. Nature 600: 472−477. DOI: 10.1038/s41586-021-03767-x. [88] Horowitz, J.E., Kosmicki, J.A., Damask, A., et al. (2022). Genome-wide analysis provides genetic evidence that ACE2 influences COVID-19 risk and yields risk scores associated with severe disease. Nat. Genet. 54: 382−392. DOI: 10.1038/s41588-021-01006-7. [89] Zhang, Q., Bastard, P., Liu, Z., et al. (2020). Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 370: eabd4570. DOI: 10.1126/science.abd4570. [90] Ge, T., Chen, C.Y., Ni, Y., et al. (2019). Polygenic prediction via Bayesian regression and continuous shrinkage priors. Nat. Commun. 10: 1776. DOI: 10.1038/s41467-019-09718-5. [91] Fiziev, P.P., McRae, J., Ulirsch, J.C., et al. (2023). Rare penetrant mutations confer severe risk of common diseases. Science 380: eabo1131. DOI: 10.1126/science.abo1131. [92] Frazer, J., Notin, P., Dias, M., et al. (2021). Disease variant prediction with deep generative models of evolutionary data. Nature 599: 91−95. DOI: 10.1038/s41586-021-04043-8. [93] Zanini, F., Robinson, M.L., Croote, D., et al. (2018). Virus-inclusive single-cell RNA sequencing reveals the molecular signature of progression to severe dengue. Proc. Natl. Acad. Sci. U. S. A. 115: E12363−E12369. DOI: 10.1073/pnas.1813819115. [94] Kotliar, D., Lin, A.E., Logue, J., et al. (2020). Single-cell profiling of ebola virus disease in vivo reveals viral and host dynamics. Cell 183: 1383−1401. DOI: 10.1016/j.cell.2020.10.002. [95] Bost, P., Giladi, A., Liu, Y., et al. (2020). Host-viral infection maps reveal signatures of severe COVID-19 patients. Cell 181: 1475−1488. DOI: 10.1016/j.cell.2020.05.006. [96] Aquino, Y., Bisiaux, A., Li, Z., et al. (2023). Dissecting human population variation in single-cell responses to SARS-CoV-2. Nature 621: 120−128. DOI: 10.1038/s41586-023-06422-9. [97] Ren, X., Wen, W., Fan, X., et al. (2021). COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas. Cell 184: 1895−1913. DOI: 10.1016/j.cell.2021.01.053. [98] Stephenson, E., Reynolds, G., Botting, R.A., et al. (2021). Single-cell multi-omics analysis of the immune response in COVID-19. Nat. Med. 27: 904−916. DOI: 10.1038/s41591-021-01329-2. [99] Wang, J., Ma, A., Chang, Y., et al. (2021). scGNN is a novel graph neural network framework for single-cell RNA-Seq analyses. Nat. Commun. 12: 1882. DOI: 10.1038/s41467-021-22197-x. [100] Amodio, M., van Dijk, D., Srinivasan, K., et al. (2019). Exploring single-cell data with deep multitasking neural networks. Nat. Methods 16: 1139−1145. DOI: 10.1038/s41592-019-0576-7. [101] Xiong, L., Tian, K., Li, Y., et al. (2022). Online single-cell data integration through projecting heterogeneous datasets into a common cell-embedding space. Nat. Commun. 13: 6118. DOI: 10.1038/s41467-022-33758-z. [102] Zhao, Y., Cai, H., Zhang, Z., et al. (2021). Learning interpretable cellular and gene signature embeddings from single-cell transcriptomic data. Nat. Commun. 12: 5261. DOI: 10.1038/s41467-021-25534-2. [103] Moller, A.F. and Madsen, J.G.S. (2023). JOINTLY: Interpretable joint clustering of single-cell transcriptomes. Nat. Commun. 14: 8473. DOI: 10.1038/s41467-023-44279-8. [104] Boby, M.L., Fearon, D., Ferla, M., et al. (2023). Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors. Science 382: eabo7201. DOI. DOI: 10.1126/science.abo7201. [105] Singhal, K., Azizi, S., Tu, T., et al. (2023). Large language models encode clinical knowledge. Nature 620: 172−180. DOI: 10.1038/s41586-023-06291-2. [106] Van Veen, D., Van Uden, C., Blankemeier, L., et al. (2024). Adapted large language models can outperform medical experts in clinical text summarization. Nat. Med. 30: 1134−1142. DOI: 10.1038/s41591-024-02855-5. [107] Han, T., Adams, L.C., Bressem, K.K., et al. (2024). Comparative analysis of multimodal large language model performance on clinical vignette questions. JAMA 331: 1320−1321. DOI: 10.1001/jama.2023.27861. [108] Pais, C., Liu, J., Voigt, R., et al. (2024). Large language models for preventing medication direction errors in online pharmacies. Nat. Med. 30: 1574−1582. DOI: 10.1038/s41591-024-02933-8. [109] Tayebi Arasteh, S., Han, T., Lotfinia, M., et al. (2024). Large language models streamline automated machine learning for clinical studies. Nat. Commun. 15: 1603. DOI: 10.1038/s41467-024-45879-8. [110] Lu, M.Y., Chen, B., Williamson, D.F.K., et al. (2024). A multimodal generative AI copilot for human pathology. Nature. DOI: 10.1038/s41586-024-07618-3. [111] Boiko, D.A., MacKnight, R., Kline, B., et al. (2023). Autonomous chemical research with large language models. Nature 624: 570−578. DOI: 10.1038/s41586-023-06792-0. [112] Cui, H., Wang, C., Maan, H., et al. (2024). scGPT: Toward building a foundation model for single-cell multi-omics using generative AI. Nat. Methods DOI: 10.1038/s41592-024-02201-0. -
ABOUT THIS ARTICLE
Cite this article:
Zhou H., Li Y., Li J., et al., (2024). Harnessing the power of artificial intelligence to combat infectious diseases: Progress, challenges, and future outlook. The Innovation Medicine 2(4): 100091. https://doi.org/10.59717/j.xinn-med.2024.100091
Welcome!
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.
Export File
Citation
Zhou H., Li Y., Li J., et al., (2024). Harnessing the power of artificial intelligence to combat infectious diseases: Progress, challenges, and future outlook. The Innovation Medicine 2(4): 100091. https://doi.org/10.59717/j.xinn-med.2024.100091
Format
Content
-
Figure 1.
The schematic representation of AI utilization in infectious disease research
-
Figure 2.
Applications of AI in predicting infectious disease emergence
-
Figure 3.
The application of AI technologies in infectious disease surveillance
-
Figure 4.
The role of AI technologies in disease diagnosis and epidemic control
-
Figure 5.
Exploiting AI technologies to unravel host susceptibility and pathogenic mechanisms
-
Figure 6.
The challenges of implementing AI in infectious disease research
